Issue No. 5 · Week of September 14, 2026
This week’s clearest signal was how far a single recalled component keeps traveling: the Huons-linked saline flush ampule resurfaced in Medical Action Industries’ epidural kits, the same cascade that hit Medline’s bupivacaine kits weeks ago, while Boston Scientific’s cyberattack recovery is now bleeding into its 2026 financial guidance and into how hospitals expect vendors to handle supply chain risk.
On the access side, Canada’s counter-tariffs took effect September 8 with public health remission relief still intact for hospital and clinical imports, and Health Canada opened its recognized standards list for comment through September 25. If you ship finished kits or components into North America, this is a good week to check your own traceability records and confirm whether your Canadian shipments qualify for the health care remission.
Hospitals and Health Systems
Hospital supply chain teams now write playbooks for vendor cyberattacks
After an August cyberattack disrupted Boston Scientific’s worldwide order and shipment processing for weeks, hospital supply chain leaders described their standard response: assess inventory exposure, hold daily huddles with suppliers, and keep pre-vetted substitute products on hand. Hospitals now expect vendors to treat supply chain resilience as part of patient care, not just IT, a bar every manufacturer should be ready to meet.
Source: Becker’s Hospital Review – September 4, 2026
Alberta begins design work on a 320 million dollar cardiac and ICU expansion in Lethbridge
Alberta Health Services began design work on a redevelopment of Chinook Regional Hospital that expands the cardiac catheterization lab and grows combined ICU and cardiac care capacity to 54 beds, with construction targeted for October 2027 and completion by the end of 2031. It is a large, funded, multi year Canadian capital project worth tracking early for eventual cath lab, monitoring and critical care equipment tenders.
Source: ReNew Canada – September 8, 2026
Federal Health Systems: VA and DoD
Bluejay Diagnostics signs an SDVOSB distributor to reach VA, DoD and Indian Health Service
Bluejay Diagnostics named Lovell Government Services, a Service-Disabled Veteran-Owned Small Business, as its exclusive distributor for federal set-asides covering roughly 170 VA medical centers, 45 DoD hospitals and the Indian Health Service, systems with a combined FY2026 budget near 237 billion dollars. Bluejay’s device is still pending FDA clearance, so this is a clear illustration of how SDVOSB distributors are used as the access point into federal contracts a non-U.S. company cannot bid on directly.
Source: GlobeNewswire – September 8, 2026
DLA adds Hill-Rom and Peter Brasseler to its medical and dental equipment catalog
The Defense Logistics Agency added Hill-Rom to a 42.5 million dollar multiple award contract for medical equipment and Peter Brasseler Holdings to a 42 million dollar contract for dental supplies, both on its Electronic Catalog. DLA’s ECAT contracts are a standing channel through which device makers sell directly into military treatment facilities, and new awardees are worth watching as a model for federal market access.
Regulatory: FDA and Health Canada
Boston Scientific spinal cord stimulator leads recalled as Class I after 1,081 injuries
FDA classified Boston Scientific’s Infinion CX lead recall as Class I after mechanical stress at the anchor site caused lead fractures and loss of pain control stimulation, tied to more than 1,081 reported injuries. The recall covers only unused leads still in the field, and it is a clear reminder of how quickly a manufacturing tolerance issue can escalate into a full CAPA and field correction obligation.
Source: MedTech Dive – September 4, 2026
Draeger flags cracked hoses on its infant breathing circuit before any injuries are reported
FDA posted an early alert on Draeger’s VentStar Resus Neo disposable breathing circuit after hoses were found to crack and potentially detach or leak, risking desaturation or hypoxia in infants up to 22 pounds. It shows how a component level defect in a pediatric respiratory accessory can trigger an FDA posting well before a formal recall classification, worth watching for any manufacturer of similar disposables.
Source: FDA – September 3, 2026
Fresenius Medical Care’s Utah plant cited for complaint handling and inspection gaps
FDA issued a warning letter to Fresenius Medical Care’s Ogden, Utah plant after finding it underestimated complaints tied to leaking dialysis solution bags and used inspectors and test kits not qualified to detect particles in the 100 to 150 micron range. It is a reminder that complaint investigation and inspection controls, not just the finished product, draw scrutiny, and that even a large global manufacturer’s U.S. plant can be cited for basic CGMP gaps.
Source: FDA – August 25, 2026
Another Huons linked saline ampule turns up, this time in Medical Action Industries’ epidural kits
Medical Action Industries is correcting epidural kits that contain a sodium chloride flush ampule tied to the same Huons sterility recall that hit Medline’s bupivacaine kits weeks earlier. It is another entry in the same cascade, underscoring how one foreign sourced injectable component keeps surfacing inside other manufacturers’ finished kits months later, and why traceability to the component level matters.
Source: FDA – September 10, 2026
Health Canada opens its recognized standards list for comment
Health Canada opened a public consultation on additions, deletions and updates to its List of Recognized Standards for medical devices, the standards cited in licensing submissions, with comments due September 25. Anyone with a device licence application in the pipeline, or relying on a standard that may be added or dropped, should review the draft list while the window is open.
Source: Health Canada Consultation – Comments Due September 25
Import, Customs and Trade
Canada’s counter-tariffs take effect, with relief still in place for healthcare imports
Canada’s counter-tariffs of 15, 25 or 50 percent on US-origin goods took effect September 8 with little advance guidance, but Canada is extending its Surtax Remission Order framework, including relief through June 2027 for goods used by public health entities and the remission already in place for medically necessary hospital, clinic and laboratory imports. Any manufacturer shipping US-origin inputs or finished goods into Canadian hospitals should confirm now whether its products qualify for that public health remission before assuming the new surtax applies.
Also Noted
13 medical device recalls in a single week
Becker’s rounds up 13 device recalls in a single week, including Boston Scientific, GE HealthCare and Medline, plus early alerts from Draeger, Medtronic and CooperSurgical, worth a check against your own complaint files.
Source: Becker’s Hospital Review
Halton Healthcare begins 150 million dollar hospital expansion
Halton Healthcare begins a 150 million dollar, 123-bed expansion at its Oakville and Milton hospitals, a funded multi year buildout that opens a window for equipping new inpatient units.
Source: Ontario Construction News
Key Takeaways for Medical Device Manufacturers
This week’s developments reinforce three priorities for manufacturers selling into the U.S. and Canadian markets: maintain component-level traceability throughout finished kits, prepare for customers to treat cybersecurity and supply chain continuity as part of vendor performance, and keep complaint handling and inspection controls strong enough to withstand regulatory scrutiny.
Manufacturers shipping into Canada should also review whether their products qualify for public health remission from the new counter-tariffs, while companies with Canadian device licence applications in progress should review the proposed changes to Health Canada’s recognized standards list before the September 25 comment deadline.
Questions About U.S. or Canadian Market Access?
Dawa Medical supports foreign medical device manufacturers entering the U.S. market as U.S. Agent, FDA Initial Importer and Importer of Record, with 3PL warehousing and regulatory compliance support. Through TB Medical Inc., manufacturers can also access Canadian importation and distribution support.
About The Access Brief: The Access Brief summarizes publicly reported news affecting medical device manufacturers selling into the United States and Canada and reflects Dawa Medical’s own understanding. It is not legal, regulatory or binding advice, and formal advice should come from qualified counsel or a specialist consultant.
